Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
← catalyst calendarSponsored by BioNTech SE (industry) · BNTX — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
73actual
Sites
18
Countries
Singapore, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-22 | actual | When the study began enrolling |
| Primary completion | 2025-12-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-22 | actual | The whole study's end, after follow-up |
| First posted | 2022-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Biological: BNT142
Primary outcomes
what the primary-completion date above is the date OFOccurrence of treatment emergent adverse events (TEAEs) including Grade ≥3, serious, or fatal TEAEs by causal relationship to study treatment
measured From first dose to 60 days after the last dose of BNT142
Occurrence of dose reductions and discontinuation of BNT142 due to TEAEs
measured From first dose to 60 days after the last dose of BNT142
Part 1: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period in the dose escalation
measured Assessed during the DLT period, i.e., up to 5 weeks after first dose of BNT142
Part 2: Objective response rate (ORR)
measured Up to 36 months after last patient last dose
Publications
- PMID 38776391 — linked by the registry
- PMID 37592303 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed